RODRIGUEZ MORENO, C. et al. Tumor necrosis factor blocking agents: a review: Part I: Clinical efficacy evaluation. []. , 23, 1, pp.37-45. ISSN 0212-7199.

Blockade of tumor necrosis factor with monoclonal antibodies, has emerged as one of the most promising therapies in some autoimmune conditions as rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and Crohn's disease. They have shown effectiveness on reducing symptoms and modifying the progression of the disease. However, they disrupt the balance of inflammatory and immune responses and some risks associated with TNF-blockers have become apparent. The purpose of this article is to review the evidence about benefits and risk associated with the use of TNF-blockers in approved indications and to provide practical recommendations for its use in the management of this conditions.

: Tumor necrosis factor; Rheumatoid arthritis; Crohn's disease; Infliximab; Etanercept; Adalimumab; Clinical trial; Efficacy.

        · |     · |     · ( pdf )